{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T09:15:39Z","timestamp":1775898939126,"version":"3.50.1"},"reference-count":137,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FCT\u2014Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia, I.P.","award":["UIDB\/04501\/2020"],"award-info":[{"award-number":["UIDB\/04501\/2020"]}]},{"name":"FCT\u2014Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia, I.P.","award":["UIDB\/00051\/2020"],"award-info":[{"award-number":["UIDB\/00051\/2020"]}]},{"name":"FCT\u2014Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia, I.P.","award":["UIDP\/00051\/2020"],"award-info":[{"award-number":["UIDP\/00051\/2020"]}]},{"name":"FCT\u2014Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia, I.P.","award":["LA\/P\/0053\/2020"],"award-info":[{"award-number":["LA\/P\/0053\/2020"]}]},{"name":"Cardiovascular R&amp;D Center","award":["UIDB\/04501\/2020"],"award-info":[{"award-number":["UIDB\/04501\/2020"]}]},{"name":"Cardiovascular R&amp;D Center","award":["UIDB\/00051\/2020"],"award-info":[{"award-number":["UIDB\/00051\/2020"]}]},{"name":"Cardiovascular R&amp;D Center","award":["UIDP\/00051\/2020"],"award-info":[{"award-number":["UIDP\/00051\/2020"]}]},{"name":"Cardiovascular R&amp;D Center","award":["LA\/P\/0053\/2020"],"award-info":[{"award-number":["LA\/P\/0053\/2020"]}]},{"name":"RISE","award":["UIDB\/04501\/2020"],"award-info":[{"award-number":["UIDB\/04501\/2020"]}]},{"name":"RISE","award":["UIDB\/00051\/2020"],"award-info":[{"award-number":["UIDB\/00051\/2020"]}]},{"name":"RISE","award":["UIDP\/00051\/2020"],"award-info":[{"award-number":["UIDP\/00051\/2020"]}]},{"name":"RISE","award":["LA\/P\/0053\/2020"],"award-info":[{"award-number":["LA\/P\/0053\/2020"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Prostate cancer remains a major global health challenge, ranking as the second most common malignancy in men worldwide. Advances in diagnostic and therapeutic strategies have transformed its management, enhancing patient outcomes and quality of life. This review highlights recent breakthroughs in imaging, including multiparametric MRI and PSMA-PET, which have improved cancer detection and staging. Biomarker-based diagnostics, such as PHI and 4K Score, offer precise risk stratification, reducing unnecessary biopsies. Innovations in treatment, including robotic-assisted surgery, novel hormone therapies, immunotherapy, and PARP inhibitors, are redefining care for localized and advanced prostate cancer. Artificial intelligence (AI) and machine learning (ML) are emerging as powerful tools to optimize diagnostics, risk prediction, and treatment personalization. Additionally, advances in radiation therapy, such as IMRT and SBRT, provide targeted and effective options for high-risk patients. While these innovations have significantly improved survival and minimized overtreatment, challenges remain in optimizing therapy sequencing and addressing disparities in care. The integration of AI, theranostics, and gene-editing technologies holds immense promise for the future of prostate cancer management.<\/jats:p>","DOI":"10.3390\/ijms26115386","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T08:51:04Z","timestamp":1749027064000},"page":"5386","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Transforming Prostate Cancer Care: Innovations in Diagnosis, Treatment, and Future Directions"],"prefix":"10.3390","volume":"26","author":[{"given":"Sanaz","family":"Vakili","sequence":"first","affiliation":[{"name":"Department of Human Anatomy and Cell Science, University of Manitoba College of Medicine, Winnipeg, MB R3E 3P5, Canada"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4750-3433","authenticated-orcid":false,"given":"Iman","family":"Beheshti","sequence":"additional","affiliation":[{"name":"Department of Human Anatomy and Cell Science, University of Manitoba College of Medicine, Winnipeg, MB R3E 3P5, Canada"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8113-5809","authenticated-orcid":false,"given":"Amir","family":"Barzegar Behrooz","sequence":"additional","affiliation":[{"name":"Department of Human Anatomy and Cell Science, University of Manitoba College of Medicine, Winnipeg, MB R3E 3P5, Canada"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9518-1411","authenticated-orcid":false,"given":"Marek J.","family":"\u0141os","sequence":"additional","affiliation":[{"name":"Biotechnology Center, Silesian University of Technology, 44-100 Gliwice, Poland"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3636-5805","authenticated-orcid":false,"given":"Rui","family":"Vitorino","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Institute of Biomedicine iBiMED, University of Aveiro, 3810-193 Aveiro, Portugal"},{"name":"Department of Surgery and Physiology, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5948-508X","authenticated-orcid":false,"given":"Saeid","family":"Ghavami","sequence":"additional","affiliation":[{"name":"Department of Human Anatomy and Cell Science, University of Manitoba College of Medicine, Winnipeg, MB R3E 3P5, Canada"},{"name":"Biology of Breathing Theme, Children Hospital Research Institute of Manitoba, University of Manitoba, Winnipeg, MB R3T 2N2, Canada"},{"name":"Faculty of Medicine, Akademia \u015al\u0105ska, Rolna 43, 40-555 Katowice, Poland"},{"name":"Paul Albrechtsen Research Institute, CancerCare Manitoba, University of Manitoba, Winnipeg, MB R3E 0V9, Canada"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.5694\/mja2.51722","article-title":"Modern paradigms for prostate cancer detection and management","volume":"217","author":"Williams","year":"2022","journal-title":"Med. J. Aust."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","article-title":"2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review","volume":"84","author":"Bergengren","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"862639","DOI":"10.1155\/2012\/862639","article-title":"Current Challenges in Prostate Cancer Management and the Rationale behind Targeted Focal Therapy","volume":"2012","author":"Barqawi","year":"2012","journal-title":"Adv. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40164-023-00444-9","article-title":"Recent advances and future perspectives in the therapeutics of prostate cancer","volume":"12","author":"Varaprasad","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"a030635","DOI":"10.1101\/cshperspect.a030635","article-title":"Treatment of Advanced Prostate Cancer\u2014A Review of Current Therapies and Future Promise","volume":"8","author":"Sumanasuriya","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Wang, L., Lu, B., He, M., Wang, Y., Wang, Z., and Du, L. (2022). Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.811044"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of Prostate Cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J. Oncol."},{"key":"ref_8","first-page":"122","article-title":"Current clinical challenges in prostate cancer","volume":"2","author":"Silberstein","year":"2013","journal-title":"Transl. Androl. Urol."},{"key":"ref_9","first-page":"e73128","article-title":"Innovations and Emerging Trends in Prostate Cancer Management: A Literature Review","volume":"16","author":"Ibraheem","year":"2024","journal-title":"Cureus"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): A paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2967\/jnumed.117.197160","article-title":"The Impact of 68Ga-PSMA PET\/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study","volume":"59","author":"Roach","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"805","DOI":"10.5114\/aoms.2019.85252","article-title":"Active surveillance in prostate cancer management: Where do we stand now?","volume":"17","author":"Dragan","year":"2021","journal-title":"Arch. Med. Sci."},{"key":"ref_13","first-page":"435","article-title":"Focal therapy in prostate cancer: The current situation","volume":"8","author":"Barret","year":"2014","journal-title":"Ecancermedicalscience"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"391437","DOI":"10.1155\/2012\/391437","article-title":"Focal therapy in the management of prostate cancer: An emerging approach for localized prostate cancer","volume":"2012","author":"Nomura","year":"2012","journal-title":"Adv. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Yang, C.H., Barbulescu, D.V., Marian, L., Tung, M.C., Ou, Y.C., and Wu, C.H. (2024). High-Intensity Focus Ultrasound Ablation in Prostate Cancer: A Systematic Review. J. Pers. Med., 14.","DOI":"10.3390\/jpm14121163"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Ghoreifi, A., Gomella, L., Hu, J.C., Konety, B., Lunelli, L., Rastinehad, A.R., Salomon, G., Taneja, S., Tourinho-Barbosa, R., and Lebastchi, A.H. (2024). Identifying the best candidate for focal therapy: A comprehensive review. Prostate Cancer Prostatic Dis.","DOI":"10.1038\/s41391-024-00907-y"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Raju, R., Sahu, A., Klevansky, M., and Torres, J. (2021). Real-World Data on Outcomes in Metastatic Castrate-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide: A Regional Experience. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.656146"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1007\/s12325-022-02085-6","article-title":"Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents","volume":"39","author":"Hafron","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Xia, M., Guo, Z., and Hu, Z. (2021). The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials. Biomolecules, 11.","DOI":"10.3390\/biom11050722"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"102623","DOI":"10.1016\/j.ctrv.2023.102623","article-title":"Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials","volume":"120","author":"Iannantuono","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-021-01061-x","article-title":"Prostate cancer and PARP inhibitors: Progress and challenges","volume":"14","author":"Teyssonneau","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.clgc.2023.12.011","article-title":"PARP Inhibitors in Metastatic Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis of Existing Evidence","volume":"22","author":"Ditonno","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Taylor, A.K., Kosoff, D., Emamekhoo, H., Lang, J.M., and Kyriakopoulos, C.E. (2023). PARP inhibitors in metastatic prostate cancer. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1159557"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.euf.2017.11.009","article-title":"Taxane-based Combination Therapies for Metastatic Prostate Cancer","volume":"5","author":"Corn","year":"2019","journal-title":"Eur. Urol. Focus"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Kwon, W.A., Song, Y.S., and Lee, M.K. (2024). Strategic Advances in Combination Therapy for Metastatic Castration-Sensitive Prostate Cancer: Current Insights and Future Perspectives. Cancers, 16.","DOI":"10.20944\/preprints202408.2024.v1"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1093\/annonc\/mdq050","article-title":"Docetaxel-based combination therapy for castration-resistant prostate cancer","volume":"21","author":"Galsky","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in Patients with Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study","volume":"39","author":"Chi","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.eururo.2023.04.002","article-title":"The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES","volume":"84","author":"Armstrong","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.euf.2022.08.007","article-title":"Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis","volume":"9","author":"Mandel","year":"2023","journal-title":"Eur. Urol. Focus"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/jamaoncol.2024.0591","article-title":"Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review","volume":"10","author":"Hussain","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"17588359221086827","DOI":"10.1177\/17588359221086827","article-title":"Combination therapy in metastatic hormone-sensitive prostate cancer: Is three a crowd?","volume":"14","author":"Davis","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.21873\/anticanres.17069","article-title":"Efficacy of Combination Therapy with Radium-223 and Enzalutamide in Castration-resistant Prostate Cancer with Bone Metastases","volume":"44","author":"Wakita","year":"2024","journal-title":"Anticancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Damiana, T.S.T., and Dalm, S.U. (2021). Combination Therapy, a Promising Approach to Enhance the Efficacy of Radionuclide and Targeted Radionuclide Therapy of Prostate and Breast Cancer. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13050674"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/MED.0b013e328360332a","article-title":"Prostate cancer overdiagnosis and overtreatment","volume":"20","author":"Klotz","year":"2013","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Fenton, J.J., Weyrich, M.S., Durbin, S., Liu, Y., Bang, H., and Melnikow, J.U.S. (2018). Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews, Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force.","DOI":"10.1001\/jama.2018.3712"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Barbier, M.C., Tomonaga, Y., Menges, D., Yebyo, H.G., Haile, S.R., Puhan, M.A., and Schwenkglenks, M. (2022). Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0277282"},{"key":"ref_38","first-page":"533","article-title":"The Impact of Prostate Cancer Treatment on Quality of Life: A Narrative Review with a Focus on Randomized Data","volume":"12","author":"Taylor","year":"2020","journal-title":"Res. Rep. Urol."},{"key":"ref_39","first-page":"21","article-title":"The Economic Burden of Metastatic Castration Resistant Prostate Cancer and Skeletal Related Events in Japanese University Hospitals","volume":"19","author":"Satoh","year":"2018","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0302-2838(03)00007-1","article-title":"Costs of prostate cancer, metastatic to the bone, in the Netherlands","volume":"43","author":"Groot","year":"2003","journal-title":"Eur. Urol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1177\/0272989X231201621","article-title":"Cost-Effectiveness Analysis for Therapy Sequence in Advanced Cancer: A Microsimulation Approach with Application to Metastatic Prostate Cancer","volume":"43","author":"Handorf","year":"2023","journal-title":"Med. Decis. Mak."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: Planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"ref_43","first-page":"8","article-title":"Liquid Biomarkers in Prostate Cancer Diagnosis: Current Status and Emerging Prospects","volume":"42","author":"Liu","year":"2024","journal-title":"World J. Mens Health"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.juro.2014.10.121","article-title":"The prostate health index selectively identifies clinically significant prostate cancer","volume":"193","author":"Loeb","year":"2015","journal-title":"J. Urol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.21037\/tau-20-1151","article-title":"Biomarkers for detection of clinically significant prostate cancer: Contemporary clinical data and future directions","volume":"10","author":"Eyrich","year":"2021","journal-title":"Transl. Androl. Urol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.urology.2020.11.008","article-title":"A 4Kscore Cut-off of 7.5% for Prostate Biopsy Decisions Provides High Sensitivity and Negative Predictive Value for Significant Prostate Cancer","volume":"148","author":"Bhattu","year":"2021","journal-title":"Urology"},{"key":"ref_47","first-page":"149","article-title":"Clinical performance of the 4Kscore Test to predict high-grade prostate cancer at biopsy: A meta-analysis of us and European clinical validation study results","volume":"19","author":"Zappala","year":"2017","journal-title":"Rev. Urol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"Fso72","DOI":"10.4155\/fso.15.72","article-title":"Biomarkers for prostate cancer: Present challenges and future opportunities","volume":"2","author":"Sharma","year":"2016","journal-title":"Future Sci. OA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.euo.2021.03.002","article-title":"Development of a Whole-urine, Multiplexed, Next-generation RNA-sequencing Assay for Early Detection of Aggressive Prostate Cancer","volume":"5","author":"Cani","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/jnci\/djj131","article-title":"Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial","volume":"98","author":"Thompson","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.juro.2015.10.140","article-title":"The Diagnostic Performance of Multiparametric Magnetic Resonance Imaging to Detect Significant Prostate Cancer","volume":"195","author":"Thompson","year":"2016","journal-title":"J. Urol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.eururo.2015.01.013","article-title":"Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature","volume":"68","author":"Briganti","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Chen, J.-Y., Wang, P.-Y., Liu, M.-Z., Lyu, F., Ma, M.-W., Ren, X.-Y., and Gao, X.-S. (2023). Biomarkers for Prostate Cancer: From Diagnosis to Treatment. Diagnostics, 13.","DOI":"10.3390\/diagnostics13213350"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1007\/s00261-023-04002-z","article-title":"PSMA PET imaging in the diagnosis and management of prostate cancer","volume":"48","author":"Houshmand","year":"2023","journal-title":"Abdom. Radiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"17588359231208960","DOI":"10.1177\/17588359231208960","article-title":"Current role of PSMA-PET imaging in the clinical management of prostate cancer","volume":"15","author":"Georgakopoulos","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","article-title":"Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer\u2014Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis","volume":"77","author":"Perera","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Alshamrani, A.F.A. (2024). Diagnostic Accuracy of Molecular Imaging Techniques for Detecting Prostate Cancer: A Systematic Review. Diagnostics, 14.","DOI":"10.3390\/diagnostics14131315"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jama.2014.17942","article-title":"Comparison of MR\/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer","volume":"313","author":"Siddiqui","year":"2015","journal-title":"JAMA"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1007\/s00345-020-03392-9","article-title":"PSA-based machine learning model improves prostate cancer risk stratification in a screening population","volume":"39","author":"Perera","year":"2021","journal-title":"World J. Urol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"EVIDoa2300023","DOI":"10.1056\/EVIDoa2300023","article-title":"Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer","volume":"2","author":"Spratt","year":"2023","journal-title":"NEJM Evid."},{"key":"ref_61","first-page":"e46021","article-title":"Exploring the Use of Artificial Intelligence and Robotics in Prostate Cancer Management","volume":"15","author":"Arigbede","year":"2023","journal-title":"Cureus"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"100501","DOI":"10.1016\/j.phro.2023.100501","article-title":"Real-world validation of Artificial Intelligence-based Computed Tomography auto-contouring for prostate cancer radiotherapy planning","volume":"28","author":"Palazzo","year":"2023","journal-title":"Phys. Imaging Radiat. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"161.e1","DOI":"10.1016\/j.urolonc.2021.08.007","article-title":"A machine learning approach to predict progression on active surveillance for prostate cancer","volume":"40","author":"Nayan","year":"2022","journal-title":"Urol. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"216739","DOI":"10.1016\/j.canlet.2024.216739","article-title":"Identification of a 9-gene signature to enhance biochemical recurrence prediction in primary prostate cancer: A benchmarking study using ten machine learning methods and twelve patient cohorts","volume":"588","author":"Yin","year":"2024","journal-title":"Cancer Lett."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Hong, J.C., Eclov, N.C.W., Stephens, S.J., Mowery, Y.M., and Palta, M. (2022). Implementation of machine learning in the clinic: Challenges and lessons in prospective deployment from the System for High Intensity EvaLuation During Radiation Therapy (SHIELD-RT) randomized controlled study. BMC Bioinform., 23.","DOI":"10.1186\/s12859-022-04940-3"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Chen, S., Jian, T., Chi, C., Liang, Y., Liang, X., Yu, Y., Jiang, F., and Lu, J. (2022). Machine Learning-Based Models Enhance the Prediction of Prostate Cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.941349"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/PAP.0000000000000425","article-title":"Artificial Intelligence-Enabled Prostate Cancer Diagnosis and Prognosis: Current State and Future Implications","volume":"31","author":"Satturwar","year":"2024","journal-title":"Adv. Anat. Pathol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.zemedi.2023.05.001","article-title":"Automatic AI-based contouring of prostate MRI for online adaptive radiotherapy","volume":"34","author":"Nachbar","year":"2024","journal-title":"Z. Med. Phys."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2214\/AJR.21.26917","article-title":"Artificial Intelligence for Automated Cancer Detection on Prostate MRI: Opportunities and Ongoing Challenges, From the AJR Special Series on AI Applications","volume":"219","author":"Turkbey","year":"2022","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41591-021-01620-2","article-title":"Artificial intelligence for diagnosis and Gleason grading of prostate cancer: The PANDA challenge","volume":"28","author":"Bulten","year":"2022","journal-title":"Nat. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.eururo.2022.07.028","article-title":"Re: Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer: The PANDA Challenge","volume":"82","author":"Dasgupta","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.euf.2021.07.002","article-title":"Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer in Biopsies-Current Status and Next Steps","volume":"7","author":"Kartasalo","year":"2021","journal-title":"Eur. Urol. Focus"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.urolonc.2021.03.012","article-title":"Artificial intelligence in urological oncology: An update and future applications","volume":"39","author":"Brodie","year":"2021","journal-title":"Urol. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1177\/08465371231152230","article-title":"Applications of Artificial Intelligence in Urological Oncology Imaging: More Data Are Needed","volume":"74","author":"Soyer","year":"2023","journal-title":"Can. Assoc. Radiol. J."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"101506","DOI":"10.1016\/j.xcrm.2024.101506","article-title":"Harnessing artificial intelligence for prostate cancer management","volume":"5","author":"Zhu","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Chaddad, A., Tan, G., Liang, X., Hassan, L., Rathore, S., Desrosiers, C., Katib, Y., and Niazi, T. (2023). Advancements in MRI-Based Radiomics and Artificial Intelligence for Prostate Cancer: A Comprehensive Review and Future Prospects. Cancers, 15.","DOI":"10.3390\/cancers15153839"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"121","DOI":"10.5489\/cuaj.11085","article-title":"Pre-treatment risk stratification of prostate cancer patients: A critical review","volume":"6","author":"Rodrigues","year":"2012","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/pros.24537","article-title":"Development and validation of a simple prostate cancer risk prediction model based on age, family history, and polygenic risk","volume":"83","author":"Dite","year":"2023","journal-title":"Prostate"},{"key":"ref_79","first-page":"e66225","article-title":"A Comprehensive Review of Artificial Intelligence in Prostate Cancer Care: State-of-the-Art Diagnostic Tools and Future Outlook","volume":"16","author":"Agrawal","year":"2024","journal-title":"Cureus"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Tapper, W., Carneiro, G., Mikropoulos, C., Thomas, S.A., Evans, P.M., and Boussios, S. (2024). The Application of Radiomics and AI to Molecular Imaging for Prostate Cancer. J. Pers. Med., 14.","DOI":"10.3390\/jpm14030287"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/j.semnuclmed.2023.06.001","article-title":"Applications of Artificial Intelligence in PSMA PET\/CT for Prostate Cancer Imaging","volume":"54","author":"Frantz","year":"2024","journal-title":"Semin. Nucl. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"17562872221128791","DOI":"10.1177\/17562872221128791","article-title":"A review of artificial intelligence in prostate cancer detection on imaging","volume":"14","author":"Bhattacharya","year":"2022","journal-title":"Ther. Adv. Urol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/jmai.2019.04.02","article-title":"Artificial intelligence in radiation oncology treatment planning: A brief overview","volume":"2","author":"Kiser","year":"2019","journal-title":"J. Med. Artif. Intell."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ucl.2023.06.006","article-title":"Genomics and Artificial Intelligence: Prostate Cancer","volume":"51","author":"Wong","year":"2024","journal-title":"Urol. Clin. N. Am."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00428-023-03518-5","article-title":"Artificial intelligence-assisted cancer diagnosis improves the efficiency of pathologists in prostatic biopsies","volume":"482","author":"Eloy","year":"2023","journal-title":"Virchows Arch."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Rabaan, A.A., Bakhrebah, M.A., AlSaihati, H., Alhumaid, S., Alsubki, R.A., Turkistani, S.A., Al-Abdulhadi, S., Aldawood, Y., Alsaleh, A.A., and Alhashem, Y.N. (2022). Artificial Intelligence for Clinical Diagnosis and Treatment of Prostate Cancer. Cancers, 14.","DOI":"10.3390\/cancers14225595"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e230149","DOI":"10.1148\/rycan.230149","article-title":"AI-enhanced Mammography with Digital Breast Tomosynthesis for Breast Cancer Detection: Clinical Value and Comparison with Human Performance","volume":"6","author":"Resch","year":"2024","journal-title":"Radiol. Imaging Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1001\/jamaoncol.2017.5667","article-title":"A Magnetic Resonance Imaging-Based Prediction Model for Prostate Biopsy Risk Stratification","volume":"4","author":"Mehralivand","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Osses, D.F., Roobol, M.J., and Schoots, I.G. (2019). Prediction Medicine: Biomarkers, Risk Calculators and Magnetic Resonance Imaging as Risk Stratification Tools in Prostate Cancer Diagnosis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20071637"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"111581","DOI":"10.1016\/j.ejrad.2024.111581","article-title":"AI-based automated evaluation of image quality and protocol tailoring in patients undergoing MRI for suspected prostate cancer","volume":"177","author":"Kluckert","year":"2024","journal-title":"Eur. J. Radiol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1057\/s41599-023-02079-x","article-title":"Ethics and discrimination in artificial intelligence-enabled recruitment practices","volume":"10","author":"Chen","year":"2023","journal-title":"Humanit. Soc. Sci. Commun."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1200\/JCO.22.01453","article-title":"CanRisk-Prostate: A Comprehensive, Externally Validated Risk Model for the Prediction of Future Prostate Cancer","volume":"41","author":"Nyberg","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_93","unstructured":"American Cancer Society (2025, May 28). What\u2019s New in Prostate Cancer Research? Overview of Bladder Cancer. Available online: https:\/\/www.cancer.org\/cancer\/types\/prostate-cancer\/about\/new-research.html."},{"key":"ref_94","unstructured":"UC Urology & Oncology (2025, May 28). New Advances in Prostate Cancer Treatment Options. Available online: https:\/\/www.kcuc.com\/new-advances-in-prostate-cancer-treatment-options\/."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Nevedomskaya, E., Baumgart, S.J., and Haendler, B. (2018). Recent Advances in Prostate Cancer Treatment and Drug Discovery. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19051359"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1200\/OP.21.00206","article-title":"Recent Advances in the Management of Metastatic Prostate Cancer","volume":"18","author":"Sayegh","year":"2022","journal-title":"JCO Oncol. Pract."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2217\/fon-2017-0531","article-title":"Sipuleucel-T for the treatment of prostate cancer: Novel insights and future directions","volume":"14","author":"Handy","year":"2018","journal-title":"Future Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.trecan.2020.04.010","article-title":"Advanced Prostate Cancer: Treatment Advances and Future Directions","volume":"6","author":"Swami","year":"2020","journal-title":"Trends Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.trecan.2023.06.009","article-title":"Advances in the treatment of metastatic prostate cancer","volume":"9","author":"Gebrael","year":"2023","journal-title":"Trends Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1208\/s12249-024-02765-2","article-title":"Recent Trends in Nanocarrier-Based Drug Delivery System for Prostate Cancer","volume":"25","author":"Kumar","year":"2024","journal-title":"AAPS PharmSciTech"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"100778","DOI":"10.1016\/j.ctarc.2023.100778","article-title":"Emerging frontiers in nanomedicine targeted therapy for prostate cancer","volume":"37","author":"Adekiya","year":"2023","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1002\/tcr.202000104","article-title":"Silica-Based Nanoparticles as Drug Delivery Vehicles for Prostate Cancer Treatment","volume":"21","author":"Tiburcius","year":"2021","journal-title":"Chem. Rec."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"He, M., Cao, Y., Chi, C., Zhao, J., Chong, E., Chin, K.X.C., Tan, N.Z.V., Dmitry, K., Yang, G., and Yang, X. (2023). Unleashing novel horizons in advanced prostate cancer treatment: Investigating the potential of prostate specific membrane antigen-targeted nanomedicine-based combination therapy. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1265751"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3892\/mco.2014.356","article-title":"Passive targeting of nanoparticles to cancer: A comprehensive review of the literature","volume":"2","author":"Bazak","year":"2014","journal-title":"Mol. Clin. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/jphp.13098","article-title":"An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites","volume":"71","author":"Attia","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_106","first-page":"571394","article-title":"Targeted delivery of nanomedicines","volume":"2012","year":"2012","journal-title":"ISRN Pharmacol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"4897515","DOI":"10.1155\/2016\/4897515","article-title":"Prostate Radiotherapy in the Era of Advanced Imaging and Precision Medicine","volume":"2016","author":"Dulaney","year":"2016","journal-title":"Prostate Cancer"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/j.seminoncol.2013.04.005","article-title":"Pushing the limits of radiation therapy for prostate cancer: Where do we go next?","volume":"40","author":"Mishra","year":"2013","journal-title":"Semin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.critrevonc.2015.02.008","article-title":"Advances in the treatment of prostate cancer with radiotherapy","volume":"95","author":"Lara","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_110","unstructured":"(2025, May 28). Image Guided Radiotherapy (IGRT). Together We Will Beat Cancer. Available online: https:\/\/www.cancerresearchuk.org\/about-cancer\/treatment\/radiotherapy\/external\/types\/image-guided-radiotherapy-igrt#:~:text=IGRT%20is%20short%20for%20image,the%20surrounding%20tissues%20and%20bones."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-3-319-99286-0_2","article-title":"Advances in Radiotherapy for Prostate Cancer Treatment","volume":"1096","author":"Podder","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_112","unstructured":"(2025, May 28). What is Proton Beam Therapy for Prostate Cancer? Proton Therapy for Prostate Cancer. Available online: https:\/\/www.hopkinsmedicine.org\/health\/conditions-and-diseases\/prostate-cancer\/proton-therapy-for-prostate-cancer."},{"key":"ref_113","first-page":"65","article-title":"MRI-Guided Radiotherapy for Prostate Cancer: A New Paradigm","volume":"61","author":"Gregov","year":"2022","journal-title":"Acta Clin. Croat."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"20210800","DOI":"10.1259\/bjr.20210800","article-title":"MR-guided radiotherapy for prostate cancer: State of the art and future perspectives","volume":"95","author":"Sritharan","year":"2022","journal-title":"Br. J. Radiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.hoc.2019.08.017","article-title":"Radiation Therapy for Prostate Cancer","volume":"34","author":"Kamran","year":"2020","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/bs.acr.2024.07.004","article-title":"Advances in prostate cancer treatment: Radionuclide therapy for prostate cancer","volume":"164","author":"Zhong","year":"2024","journal-title":"Adv. Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1158\/1078-0432.CCR-19-0624","article-title":"Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer","volume":"25","author":"Leighl","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1158\/1541-7786.MCR-23-0958","article-title":"Defining Splicing Factor Requirements for Androgen Receptor Variant Synthesis in Advanced Prostate Cancer","volume":"22","author":"Walker","year":"2024","journal-title":"Mol. Cancer Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"110417","DOI":"10.1016\/j.celrep.2022.110417","article-title":"A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer","volume":"38","author":"Tang","year":"2022","journal-title":"Cell Rep."},{"key":"ref_120","first-page":"57","article-title":"Recent advances in radiotherapy modalities for prostate cancer","volume":"61","author":"Chua","year":"2022","journal-title":"Acta Clin. Croat."},{"key":"ref_121","first-page":"8481","article-title":"Management of systemic prostate cancer: Current algorithm from castration sensitive to castration resistant setting","volume":"26","author":"Cavaliere","year":"2022","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_122","first-page":"107","article-title":"Prostate-Specific Antigen Dynamics from the Phase 3 EMBARK Trial: A Post Hoc Analysis","volume":"69","year":"2024","journal-title":"UroToday"},{"key":"ref_123","unstructured":"Institite, N.C. (2025, May 28). Enzalutamide Gets Added Approval for Prostate Cancer That Hasn\u2019t Spread, Available online: https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2024\/fda-xtandi-prostate-cancer-psa-recurrence."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11912-017-0568-7","article-title":"Mechanisms of Therapeutic Resistance in Prostate Cancer","volume":"19","author":"Nakazawa","year":"2017","journal-title":"Curr. Oncol. Rep."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/pros.23967","article-title":"Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines","volume":"80","author":"Shore","year":"2020","journal-title":"Prostate"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41698-022-00272-w","article-title":"Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance","volume":"6","author":"Ge","year":"2022","journal-title":"npj Precis. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/bjc.2017.171","article-title":"Tumour heterogeneity poses a significant challenge to cancer biomarker research","volume":"117","author":"Cyll","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41585-020-00400-w","article-title":"Genomic and phenotypic heterogeneity in prostate cancer","volume":"18","author":"Haffner","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1758835920985464","DOI":"10.1177\/1758835920985464","article-title":"Optimizing outcomes for patients with metastatic prostate cancer: Insights from South East Asia Expert Panel","volume":"13","author":"Schutz","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"9459","DOI":"10.2147\/IJN.S466396","article-title":"Synergistic Potential of Nanomedicine in Prostate Cancer Immunotherapy: Breakthroughs and Prospects","volume":"19","author":"Jiang","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41392-023-01536-y","article-title":"Nanomedicine in cancer therapy","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_132","first-page":"641","article-title":"Biodistribution and dosimetry of Lu-177 PSMA in metastasized castrate resistant prostate cancer patients","volume":"55","author":"Schuchardt","year":"2014","journal-title":"J. Nucl. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1158\/1055-9965.EPI-20-1104","article-title":"Prostate Cancer Biomarker Development: National Cancer Institute\u2019s Early Detection Research Network Prostate Cancer Collaborative Group Review","volume":"29","author":"Liss","year":"2020","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.eururo.2015.01.026","article-title":"Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer","volume":"68","author":"Higano","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13167-022-00276-3","article-title":"Prostate cancer treatment costs increase more rapidly than for any other cancer-how to reverse the trend?","volume":"13","author":"Ellinger","year":"2022","journal-title":"EPMA J."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41392-024-01760-0","article-title":"New clinical trial design in precision medicine: Discovery, development and direction","volume":"9","author":"Duan","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_137","unstructured":"Bott, S.R.J., and Ng, K.L. (2021). Combination Treatment Options for Castration-Resistant Prostate Cancer. Prostate Cancer, Exon Publications."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/11\/5386\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:46:27Z","timestamp":1760031987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/11\/5386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":137,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["ijms26115386"],"URL":"https:\/\/doi.org\/10.3390\/ijms26115386","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]}}}